Search results for "Leflunomide"

showing 3 items of 13 documents

The influence of leflunomide on cell cycle, IL-2-receptor (IL-2-R) and its gene expression

1994

Leflunomide is a novel immunomodulatory drug shown to be very effective in animal models of autoimmune diseases and transplantation rejection, as well as in human rheumatoid arthritis. Leflunomide's main metabolite, A77 1726, has been shown to be reversibly antiproliferativein vitro. Pursuing this, we performed cell cycle analysis by flow cytometry of a B-cell lymphoma line and found that at concentrations >2.5 μM cells accumulated in the early S-phase. In order to determine A77 1726's effects on cell activation, human peripheral blood lymphocytes (PBL) were cultured in the presence of PHA or OKT 3 antibody. Flow cytometric evaluation of IL-2 and transferrin receptor expression exhibited a …

Pharmacologymedicine.diagnostic_testImmunologyTransferrin receptorBiologyCell cycleToxicologyMolecular biologyFlow cytometryTransplantationGene expressionmedicinePharmacology (medical)IL-2 receptorCell activationLeflunomidemedicine.drugAgents and Actions
researchProduct

Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis

2013

Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and a significant cause of morbidity and mortality. Usual interstitial pneumonia and nonspecific interstitial pneumonia seem to be the most frequent patterns in RA patients with ILD, although the proportion of patients with usual interstitial pneumonia is higher than among patients with other systemic rheumatic autoimmune diseases. RA patients with ILD most frequently present with chronic symptoms of cough and dyspnea when climbing stairs or walking uphill. A physical examination may reveal inhalatory crackles and a pulmonary function test demonstrates restrictive physiology, often with re…

medicine.medical_specialtyImmunologyArthritisLung biopsyGastroenterologyPulmonary function testingArthritis RheumatoidAntibodies Monoclonal Murine-DerivedPatient Education as TopicUsual interstitial pneumoniaInternal medicinemedicineHumansImmunology and AllergyAntibodies BlockingPneumonitisLeflunomideClinical Trials as TopicTumor Necrosis Factor-alphabusiness.industryInterstitial lung diseaseIsoxazolesmedicine.diseaserespiratory tract diseasesMethotrexateAntirheumatic AgentsRheumatoid arthritisImmunologyLung Diseases InterstitialRituximabbusinessLeflunomidemedicine.drugExpert Review of Clinical Immunology
researchProduct

Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?

2017

Leflunomide is a member of the disease modifying anti-rheumatic drugs group used as a treatment modality in active rheumatoid and psoriatic arthritis. “Oral ulcers” are reported in 3-5% of leflunomide medicated rheumatoid arthritis patients with adverse events, but they are not described in detail in the literature. We present a case of an ulcer in the tongue of a rheumatoid arthritis patient managed with leflunomide and contemplate on its pathogenesis. Key words:Leflunomide, oral ulcer, DHODH.

musculoskeletal diseasesmedicine.medical_specialtyCase ReportOdontologíaDisease030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritis0302 clinical medicineTonguemedicineOral ulcersskin and connective tissue diseasesAdverse effectGeneral DentistryLeflunomide030203 arthritis & rheumatologyOral Medicine and Pathologybusiness.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludDermatology3. Good healthSurgerymedicine.anatomical_structureAdverse drug eventRheumatoid arthritisUNESCO::CIENCIAS MÉDICASbusinessmedicine.drugJournal of Clinical and Experimental Dentistry
researchProduct